Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Intralaboratory reproducibility of HER2 testing in breast cancer by immunohistochemistry and comparison of results obtained by different assays].

Yang Y, Wei B, Zhang Z, Tang Y, Fu J, Liao DY, Li FY, Bu H.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):29-34. Chinese.

PMID:
19489222
2.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

3.

Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.

Gouvêa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H.

Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):103-8.

PMID:
16540740
4.
5.

Evaluating HER2 amplification and overexpression in breast cancer.

Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG.

J Pathol. 2001 Nov;195(4):422-8.

PMID:
11745673
6.

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

PMID:
17536315
7.

Validation of a fully automated HER2 staining kit in breast cancer.

Moelans CB, Kibbelaar RE, van den Heuvel MC, Castigliego D, de Weger RA, van Diest PJ.

Cell Oncol. 2010;32(1-2):149-55. doi: 10.3233/CLO-2010-0514.

8.

False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.

Nunes CB, Rocha RM, Buzelin MA, Balabram D, de Souza Foureaux F, Porto SS, Gobbi H.

J Clin Pathol. 2013 Nov;66(11):946-50. doi: 10.1136/jclinpath-2013-201647. Epub 2013 Jul 18.

PMID:
23867547
9.
10.
11.

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J.

Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.

12.

Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.

Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN, Gobbi H.

J Clin Pathol. 2008 Aug;61(8):934-8. doi: 10.1136/jcp.2007.053892. Epub 2008 May 12.

PMID:
18474540
13.
14.

Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.

Bánkfalvi A, Simon R, Brandt B, Bürger H, Vollmer I, Dockhorn-Dworniczak B, Lellé RJ, Boecker W.

Histopathology. 2000 Nov;37(5):411-9.

PMID:
11119122
15.

A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast.

Sampatanukul P, Chaiwun B, Wongwaisayawan S, Suwanagool P, Vinyuvat S, Karalak A, Praditphol N, Paueksakon P, Ruangvejvorachai P, Field AS, Wannakrairot P.

J Med Assoc Thai. 2005 Nov;88(11):1680-8.

PMID:
16471119
16.

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.

Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC.

J Clin Pathol. 2007 Sep;60(9):1001-5. Epub 2006 Dec 8.

17.

[Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].

Lee JW, Noh WC, Kim MS, Kim HA, Chang YH, Hong YJ, Hong SI, Lee JK.

Korean J Lab Med. 2008 Oct;28(5):392-9. doi: 10.3343/kjlm.2008.28.5.392. Korean.

18.

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.

BMC Cancer. 2010 Oct 7;10:534. doi: 10.1186/1471-2407-10-534.

19.

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

Kovács A, Stenman G.

Pathol Res Pract. 2010 Jan 15;206(1):39-42. doi: 10.1016/j.prp.2009.08.003. Epub 2009 Oct 12.

PMID:
19819642
20.

HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.

Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C.

World J Gastroenterol. 2013 Oct 14;19(38):6438-46. doi: 10.3748/wjg.v19.i38.6438.

Supplemental Content

Support Center